Multiple Myeloma
Conditions
Brief summary
This study evaluates the outcomes of patients undergoing initial therapy for multiple myeloma.
Detailed description
PRIMARY OBJECTIVE: I. Compare the overall survival between bortezomib, lenalidomide and dexamethasone (VRd), daratumumab, lenalidomide and dexamethasone (DRd) and daratumumab, bortezomib, lenalidomide and dexamethasone (DVRd) used as initial therapy for patients with newly diagnosed MM. OUTLINE: This is an observational study. Patients have their medical records reviewed on study.
Interventions
OTHERNon-Interventional Study
Non-interventional study
Sponsors
Mayo Clinic
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Previously untreated active multiple myeloma starting a new treatment for the disease with one of the three established treatment regimens: VRd (bortezomib, lenalidomide, dexamethasone), DRd (daratumumab lenalidomide dexamethasone), or DVRd (daratumumab, bortezomib, lenalidomide, and dexamethasone) * No prior treatment for myeloma * Not receiving concurrent treatment for another active malignancy * No more than 3 months from start of treatment
Exclusion criteria
* Does not meet all inclusion criteria
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | Every 3 months, up to 10 years | Overall survival, defined as the time from initiation of therapy to the time of death due to any cause, will be assessed by review of medical record, contacting the participant, or contacting the participant's local physician every 3 months for up to 10 years after participant starts the study. |
Countries
United States
Outcome results
None listed